Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14849269 | 0.76 | KCNJ1 (0.38) | KCNJ1KCNH2MAOAMAOBACHE | |
| SCHEMBL10177027 | 0.74 | KCNJ1 (0.42) | KCNJ1KCNH2MAOAMAOBALOX5 | |
| SCHEMBL18704863 | 0.72 | KCNJ1 (0.36) | KCNJ1KCNH2MAOAMAOBACHE | |
| SCHEMBL19403178 | 0.69 | KCNJ1 (0.59) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL26110766 | 0.68 | — | — | |
| SCHEMBL29568743 | 0.65 | KCNJ1 (0.51) | KCNJ1KCNH2MAOAMAOBACHE | |
| SCHEMBL7639394 | 0.65 | KCNJ1 (0.51) | KCNJ1KCNH2MAOAMAOBACHE | |
| SCHEMBL18812259 | 0.65 | PRMT5 (0.39) | KCNJ1MAOAMAOBACHEALDH1A1 | |
| SCHEMBL15036782 | 0.64 | KCNJ1 (0.64) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL286354 | 0.64 | KCNJ1 (0.46) | KCNJ1KCNH2MAOAMAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275302-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275302-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 18/4885MAOA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.